TransMedics Group, Inc. (TMDX)
$
134.25
+1.37 (1.02%)
Key metrics
Financial statements
Free cash flow per share
3.5367
Market cap
4.6 Billion
Price to sales ratio
8.1008
Debt to equity
1.4621
Current ratio
7.6893
Income quality
1.9396
Average inventory
41.7 Million
ROE
0.3142
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
TransMedics Group, Inc. is a commercial-stage medical technology company focused on revolutionizing organ transplant therapy for patients with end-stage organ failure, both in the United States and globally. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that employs proprietary technology to provide near-physiologic conditions for donor organs outside the human body. Among its offerings, OCS LUNG preserves standard criteria donor lungs for double-lung transplantation, OCS Heart enables the extracorporeal perfusion and preservation of donor hearts, and OCS Liver is dedicated to the preservation of donor livers. The company reported an income before tax of $35,780,000.00 showcasing its pre-tax profitability, while the total costs and expenses for the company are $404,044,000.00 reflecting its overall spending. The net income ratio is $0.08 reflecting the company's profitability margin, and the operating income ratio is $0.08 indicating the company's operational profitability margin. Furthermore, the net total of other income and expenses is -$1,716,000.00 reflecting non-core financial activities. In terms of investment potential, the stock is reasonably priced at $122.29 appealing to a broad range of investors. It also boasts a high average trading volume of 724,280.00 indicating strong liquidity in the market. With a mid-range market capitalization of $4,587,903,131.00 TransMedics is recognized as a steady performer among its peers. The company operates as a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth, thereby positioning itself as a vital entity in the advancement of medical technology for organ transplantation.
Is TransMedics Group, Inc. (TMDX) a good investment?
Investing in TransMedics Group, Inc. (TMDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is TransMedics Group, Inc. (TMDX)'s stock forecast?
Analysts predict TransMedics Group, Inc. stock to fluctuate between $62.07 (low) and $156 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is TransMedics Group, Inc.'s market capitalization?
As of 2026-02-20, TransMedics Group, Inc.'s market cap is $4,587,903,131, based on 34,174,325 outstanding shares.
How does TransMedics Group, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, TransMedics Group, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy TransMedics Group, Inc. (TMDX) stock?
To buy TransMedics Group, Inc. (TMDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TMDX. Place an order (Market, Limit, etc.).
What is the best time to invest in TransMedics Group, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did TransMedics Group, Inc. perform in the last earnings report?
Revenue: $441,540,000 | EPS: $1.07 | Growth: -238.96%.
Where can I find TransMedics Group, Inc.'s investor relations reports?
Visit https://www.transmedics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for TransMedics Group, Inc.?
You can explore historical data from here
What is the all-time high and low for TransMedics Group, Inc. stock?
All-time high: $177.37 (2024-08-23) | All-time low: $10 (2022-02-24).
What are the key trends affecting TransMedics Group, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089 shares of its common stock and an aggregate of 26,549 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.
zacks.com
TransMedics secures full FDA IDE approval for its OCS ENHANCE Heart trial, clearing a key hurdle and advancing its push to expand heart transplant use.
seekingalpha.com
TransMedics: Italian NOP Program Reinforces Huge International Opportunity
zacks.com
TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.
seekingalpha.com
TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
defenseworld.net
TransMedics Group, Inc. (NASDAQ: TMDX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target
prnewswire.com
ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 44th Annual J.P.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
prnewswire.com
ANDOVER, Mass. , Dec. 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 6,333 shares of its common stock and an aggregate of 4,205 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics.
seekingalpha.com
TransMedics is reaffirmed as a buy, with significant upside potential based on improved margins and slower share dilution. I estimate 2028 revenue at $1.35 billion, driven by achieving 10k transplants at a $105,000 average price, plus $300 million in additional revenue. Net income margin is now forecast at 17.5% for 2028, with long-term potential to exceed 20%, as seen in peer medical device companies.
See all news
